Pharmacokinetics of high dosage of linezolid in two morbidly obese patients

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 8, 2015, Pages 2417-2418

  Corcione, Silvia ^a   Pagani, Nicole ^a   Baietto, Lorena ^a   Fanelli, Vito ^b   Urbino, Rosario ^b   Ranieri, V Marco ^b   Di Perri, Giovanni ^a   D'Avolio, Antonio ^a   De Rosa, Francesco G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

ICU; Obesity; PK PD; TDM

Indexed keywords

LINEZOLID; ANTIINFECTIVE AGENT;

ACUTE RESPIRATORY FAILURE; ADULT; AREA UNDER THE CURVE; BLOODSTREAM INFECTION; BODY MASS; BODY SIZE; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; HYPERCAPNIA; LETTER; LUNG LAVAGE; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MORBID OBESITY; PLASMA CLEARANCE; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CHEMISTRY; COMPLICATION; PLASMA; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; HUMANS; LINEZOLID; MALE; MIDDLE AGED; OBESITY, MORBID; PLASMA; STAPHYLOCOCCAL INFECTIONS;

EID: 84939496016     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv126     Document Type: Letter

References (9)

1. Janson B, Tursky K. Dosing of antibiotics in obesity. Curr Opin Infect Dis 2012; 25: 634-49.
2. Bhalodi AA, Papasavas PK, Tishler DS et al. Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 2013; 57: 1144-9.
3. Pea F, FurlanutM, Cojutti P et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54: 4605-10.
4. Canut A, Isla A, Betriu C et al. Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis 2012; 31: 2227-35.
5. Stein GE, Schooley SL, Peloquin CA et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39: 427-32.
6. Dong H, Wang X, Dong Y et al. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011; 38: 296-300.
7. Muzevich KM, Lee KB. Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother 2013; 47: e25.
8. Tsuji Y, Hiraki Y, Matsumoto K et al. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scand J Infect Dis 2012; 44: 626-9.
9. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-61.